Citadel Advisors’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Citadel Advisors’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-11,400	Closed	-$7K	–	10418
2018 Q4	$7K	Sell	11,400 -37,500	-77%	-$38.9K	﹤0.01%	8972
2018 Q3	$64K	Buy	48,900 +15,900	+48%	+$24.7K	﹤0.01%	8748
2018 Q2	$45K	Buy	+33,000	New	+$50.6K	﹤0.01%	8462

Citadel Advisors's AST Position: Q1 2019 in Review

Citadel Advisors sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2019, closing a stake of 35,597 shares — an estimated $22K sold.

Citadel Advisors first reported a position in AST in Q2 2015 and held it in 6 quarters. The position peaked at $97K in Q2 2015. 0 funds tracked by Wall St. Rank hold AST as of Q1 2019.

Citadel Advisors reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2019 after selling out during the quarter.
Citadel Advisors sold 35,597 Asterias Biotherapeutics Inc. Series A shares in Q1 2019, an estimated $22K.
Citadel Advisors first reported a position in Asterias Biotherapeutics Inc. Series A in Q2 2015 and held it in 6 quarters.
Citadel Advisors's Asterias Biotherapeutics Inc. Series A position peaked at $97K in Q2 2015.
0 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2019.

Based on Citadel Advisors's 13F filing for Q1 2019, filed 15 May 2019.